An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease (aGvHD)

Trial Profile

An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease (aGvHD)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2018

At a glance

  • Drugs Mobilised-peripheral-blood-cells (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Proof of concept
  • Sponsors Cellect Biotechnology
  • Most Recent Events

    • 16 Jan 2018 According to a Cellect Biotechnology media release, based on the results from the first group patients , company received an approval from the Independent Data and Safety Monitoring Board (DSMB) for dose escalation of ApoGraft FasL protein dosage to 25 ng/ml.
    • 16 Jan 2018 According to a Cellect Biotechnology media release, Company signed an agreement with Hadassah medical center to enroll patients for this clinical trial. Prof. Polina Stefenski, will be the Principal Investigator at Hadassah.
    • 04 Jan 2018 According to a Cellect Biotechnology media release, the company has completed transplantation of the first group of three patients in this trial and planning to recruit further three patients for the second cohort of patients following review of the independent data and safety monitoring board.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top